Rapport Therapeutics, Inc.

Stage 3 · Topping · week 4

As of Oct 22, 2026, Rapport Therapeutics is in Stage 3, the topping phase, now in week 4 (since Oct 1, 2026). It closed at $26.53, 49.5% below its 52-week high and below its 200-day average, which is rising.

$26.53

+2.51% today

$1.3B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is RAPP early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-06-07 → 2026-10-22

S? 42w

S1 12w

S2 27w

S2 25w

2024-06-072026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S4 10w → S1 12w → S2 27w → S3 4w → S2 25w → S3 3w current

Total tracked: 124 weeks across 7 stage runs.

RAPP among Biotechnology193rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…193	RAPPRapport Therapeutics, Inc.	Stage 3 · wk 4	53	−22.3%

vs 52W High

-49.5%

$24.37 lo$52.50 hi

49.5% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 4

1w13w26w

Week 4, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-25.8%

200 DMA: $35.74 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

2.62x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-22.3%

-34.8%

-27.0%

YTD

-5.6%

-0.9%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S3

Wk 4 · Vol 2.62x

2026-10-21S3

Wk 3 · Vol 3.86x

2026-10-20S3

Wk 3 · Vol 22.40x

2026-10-19S3

Wk 3 · Vol 0.82x

2026-10-16S3

Wk 3 · Vol 1.13x

2026-10-15S3

Wk 3 · Vol 0.92x

2026-10-14S3

Wk 2 · Vol 0.83x

2026-10-13S3

Wk 2 · Vol 0.85x

2026-10-12S3

Wk 2 · Vol 0.35x

2026-10-09S3

Wk 2 · Vol 0.68x

2026-10-08S3

Wk 2 · Vol 0.64x

2026-10-07S3

Wk 1 · Vol 0.85x

Moving averages & range

50 DMA

$39.49

200 DMA

$35.74

52W High

$52.50

52W Low

$24.37

5D Low

$25.88

Resistance levels (recent highs)

20d High

$33.91

60d High

$52.50

120d High

$52.50

250d High

$52.50

Next resistance

+27.8%

to 20d High

ROE

-40.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.0

Rapport Therapeutics: quick answers

What stage is Rapport Therapeutics in?

As of Oct 22, 2026, Rapport Therapeutics (RAPP) is in Stage 3, the topping phase. It entered Stage 3 on Oct 1, 2026 and is in week 4. What the four stages mean

Is Rapport Therapeutics in an uptrend?

Its uptrend has stalled. Rapport Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 25.8% below its 200-day average, which is rising.

How far is Rapport Therapeutics from its 52-week high?

Rapport Therapeutics closed at $26.53 on Oct 22, 2026, 49.5% below its 52-week high of $52.50. Its 52-week low is $24.37.

How has Rapport Therapeutics performed over the past year?

As of Oct 22, 2026, Rapport Therapeutics is down 0.9% over the past year and down 5.6% so far in 2026.

Which sector and industry is Rapport Therapeutics in?

Rapport Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.